Fiche traitement
transthoracic echocardiography
Centre Hospitalier Universitaire Dijon • Accident vasculaire cérébral
Suivi actif
À vérifier
Résumé
transthoracic echocardiography est développé par Centre Hospitalier Universitaire Dijon. Le traitement est actuellement en À vérifier. Il est associé à Accident vasculaire cérébral. Son objectif thérapeutique principal est Traitement symptomatique. Le statut actuel est : suivi actif.
À vérifier
Traitement symptomatique
À vérifier
Centre Hospitalier Universitaire Dijon
France
The purpose of this study is to evaluate the sensitivity and specificity of the Cardiox Flow Detection System (FDS) in identifying an intracardiac right-to-left shunt (RLS) compared to the results of transesophageal echocardiography (TEE).
RLS intracardiac shunts are associated with a number of clinically important syndromes including paradoxical thromboembolism (causing stroke or other systemic infarct), migraine headaches (particularly with aura), desaturation with obstructive sleep apnea, and decompression illness. From a research perspective, the detection of shunts in subjects with these types of syndromes is critical in helping to define the role of RLS in these disease processes. From a clinical perspective, shunt detection will be increasingly important in an era where interventional procedures for repairing cardiac defects are available for subjects determined to be at risk.
The currently accepted reference standard for detection of an intra-cardiac patent foramen ovale/atrial septal defect (PFO/ASD) RLS is a transesophageal echocardiography (TEE), a procedure that is invasive, uncomfortable, and requires conscious sedation.
Alternative options include transthoracic echocardiography (TTE) with injection of agitated saline (with and without Valsalva strain), a procedure that is far less sensitive than TEE due to the echocardiography imaging limitations seen in many adults.
Finally, transcranial Doppler (TCD) with injection of agitated saline (with and without Valsalva strain) is a newer entrant into this arena that does not require sedation or any invasive instrumentation.
The Cardiox Model 100 FDS utilizes an optical sensor positioned on the surface of the subject's skin at the scaphoid fossa of the ear. Next, a predetermined dose of an indicator dye, indocyanine green (ICG), is injected at a predetermined rate into a peripheral antecubital vein of the subject while the subject performs a breathing maneuver called a Valsalva maneuver. The exhalation by the subject into a mouthpiece connected to a pressure transducer via a flexible tubing extension, or its equivalent (ie, performing the Valsalva maneuver), is an essential step for all existing RLS detection methods. The Valsalva maneuver by the subject creates a pressure differential between the right and left sides of the heart. This Valsalva maneuver results in blood flow from the right side of the heart to the left side of the heart through an ASD, and/or causes a PFO, if present, to open, also allowing blood to flow directly from the right side to the left side of the heart without passing through the lungs (pulmonary vasculature) for oxygenation.
The Earpads, including their fluorescence sensor arrays (FSA), are used to measure the relative concentration (ie, fluorescence signal level) of ICG dye in the bloodstream as a function of time. If a premature inflection or peak occurs in the ICG dye concentration level at a time point prior to the rise and fall of the concentration associated with the main bolus of indicator, then a RLS is present in the heart. The amplitude of this premature ICG dye-dilution curve (referred to as "RLS-indicator dilution curve") is used to subsequently quantify the magnitude of the right-to-left shunt by ratiometrically comparing the amplitude of this RLS indicator dilution curve to the amplitude of the main indicator dilution curve associated with that portion of the injected ICG dye that follows the normal pathway from the right side of the heart, through the lungs, and into the left side of the heart (referred to as "normal indicator dilution curve").
2026-10-19
Début phase actuelle
Non disponible dans les sources synchronisées
Timeline clinique
À vérifier
Début phase actuelle
Non disponible dans les sources synchronisées
Préclinique
Phase 1
Phase 2
Phase 3
Approuvé
Objectif scientifique de l’étude
classification automatique vérifiable
Traitement symptomatique
Confiance automatique : 66%
Ce pourcentage n’est pas une probabilité de succès clinique.
Il mesure uniquement la force de la classification automatique de l’objectif scientifique. Le calcul part de 45 points, ajoute 7 points par unité de poids du mot-clé le plus fortement détecté, puis est plafonné à 95 %. Exemple : un score maximal de 2 donne 45 + (2 × 7) = 59 %.
Indices détectés : symptom → Traitement symptomatique
Ce score est heuristique et doit être vérifié dans le protocole ou une publication.
Description affichée depuis l’essai compatible NCT01773252, afin d’éviter le mélange entre plusieurs indications d’une même molécule.
Aucune incohérence majeure détectée entre la maladie, l’objectif et la description.
Transparence et qualité de la fiche
données vérifiablesClassificationCohérente automatiquement
Confiance de la fiche100 %
Source principaleSource officielle ou publication indexée
Dernière vérification2026-10-19
Anomalies détectées0
Validation humaineValidation humaine non effectuée
Donnée issue d’une source
Donnée normalisée automatiquement
Interprétation algorithmique
Classification scientifique multi-axes
ne pas confondre statut et résultatÉtat de l’étudeArrêtée
Disponibilité des résultatsRésultats à vérifier
InterprétationImpossible à déterminer
Niveau de preuveNon évaluable
Un essai terminé n’est pas nécessairement positif. Un essai arrêté n’est classé comme échec scientifique que lorsqu’un résultat ou une raison explicite le confirme.
Indicateurs factuels
sans score subjectifPhase enregistréeÀ vérifier
Études associées1
Publications associées11
Statut consolidéSuivi actif
Aucune chance de succès, note d’innovation, potentiel thérapeutique ou probabilité de commercialisation n’est calculé tant qu’un modèle validé et des données suffisantes ne sont pas disponibles.
Historique factuel de la molécule
15 événement(s) daté(s)Cette liste reprend uniquement les dates trouvées dans les registres et publications liés. Elle ne constitue pas une prévision.
| Date | Événement | Source |
|---|---|---|
| 2012-11-01 | Début de l’étudeNCT01773252 | Registre d’essai clinique |
| 2015-11-01 | Fin de l’étude prévue / enregistréeNCT01773252 | Registre d’essai clinique |
| 2026-07-10 | PublicationRefractory Malignant Pericardial Effusion as the Initial Presentation of Early T-Cell Precursor Acute Lymphoblastic Leukemia/Lymphoma. | Cureus |
| 2026-07-14 | PublicationParadoxical systemic manifestations from right-sided infective endocarditis via a transient intrapulmonary shunt: a case report. | European heart journal. Case reports |
| 2026-07-14 | PublicationLarge Pericardial Effusion As the Initial Presentation of Mixed Connective Tissue Disease in a Severely Malnourished Patient: A Diagnostic Challenge. | Cureus |
| 2026-07-18 | PublicationEvaluation of the protective effects of Artemisia dracunculus L. against doxorubicin-induced chronic cardio-toxicity in rat. | Fitoterapia |
| 2026-07-18 | Publication36th International Symposium on Intensive Care and Emergency Medicine : Brussels, Belgium. 15-18 March 2016. | Critical care (London, England) |
| 2026-07-24 | Création de l’enregistrementNCT01773252 | Registre d’essai clinique |
| 2026-08-08 | PublicationProceedings of the 3rd IPLeiria's International Health Congress : Leiria, Portugal. 6-7 May 2016. | BMC health services research |
| 2026-08-16 | PublicationA pathogenic nonsense mutation (c.1522C>T) of the MYBPC3 gene is implicated with hypertrophic cardiomyopathy. | ESC heart failure |
| 2026-08-16 | PublicationExtensive bilateral pulmonary embolism revealing iron deficiency-masked JAK2-positive polycythemia vera: A case report. | Radiology case reports |
| 2026-08-16 | PublicationRetrospective study on affecting factors and predictive model for guide wire failure to pass through the foramen ovale in PFO patients during interventional closure. | Medicine |
| 2026-09-01 | PublicationSynergy of Coronary Revascularization and Optimal Drug Therapy in Patients With Ischemic Cardiomyopathy and Reduced Left Ventricular Ejection Fraction. | Kardiologiia |
| 2026-10-04 | PublicationCardiac Tamponade Under Positive-Pressure Ventilation: Pathophysiological Insights and Implications for Diagnosis. | Reviews in cardiovascular medicine |
| 2026-10-19 | Dernière mise à jour des donnéestransthoracic echocardiography | Biomedical Watch |
Début phase actuelle
Non disponible dans les sources synchronisées
Essais cliniques liés
1 essai(s)
Début phase actuelle
Non disponible dans les sources synchronisées
| NCT | Titre | Phase | Statut administratif | Pays | Sponsor |
|---|---|---|---|---|---|
| NCT01773252 | PFO Detection — Right to Left Cardiac Shunt Detection | Phase 3 | TERMINATED | United States | Cardiox Corporation |
Publications liées
11 publication(s)Publications liées
11 publication(s)| Titre | PMID | DOI | Journal | Date |
|---|---|---|---|---|
| Cardiac Tamponade Under Positive-Pressure Ventilation: Pathophysiological Insights and Implications for Diagnosis. Voir source | 42416561 | 10.31083/RCM49283 | Reviews in cardiovascular medicine | |
| Synergy of Coronary Revascularization and Optimal Drug Therapy in Patients With Ischemic Cardiomyopathy and Reduced Left Ventricular Ejection Fraction. Voir source | 41671022 | 10.18087/cardio.2026.1.n3098 | Kardiologiia | |
| A pathogenic nonsense mutation (c.1522C>T) of the MYBPC3 gene is implicated with hypertrophic cardiomyopathy. Voir source | 37271167 | 10.1002/ehf2.14424 | ESC heart failure | |
| Extensive bilateral pulmonary embolism revealing iron deficiency-masked JAK2-positive polycythemia vera: A case report. Voir source | 42381746 | 10.1016/j.radcr.2026.06.035 | Radiology case reports | |
| Retrospective study on affecting factors and predictive model for guide wire failure to pass through the foramen ovale in PFO patients during interventional closure. Voir source | 41630323 | 10.1097/MD.0000000000047421 | Medicine | |
| Proceedings of the 3rd IPLeiria's International Health Congress : Leiria, Portugal. 6-7 May 2016. Voir source | 27409075 | 10.1186/s12913-016-1423-5 | BMC health services research | |
| Evaluation of the protective effects of Artemisia dracunculus L. against doxorubicin-induced chronic cardio-toxicity in rat. Voir source | 42468643 | 10.1016/j.fitote.2026.107391 | Fitoterapia | |
| 36th International Symposium on Intensive Care and Emergency Medicine : Brussels, Belgium. 15-18 March 2016. Voir source | 27885969 | 10.1186/s13054-016-1208-6 | Critical care (London, England) | |
| Paradoxical systemic manifestations from right-sided infective endocarditis via a transient intrapulmonary shunt: a case report. Voir source | 42445805 | 10.1093/ehjcr/ytag481 | European heart journal. Case reports | |
| Large Pericardial Effusion As the Initial Presentation of Mixed Connective Tissue Disease in a Severely Malnourished Patient: A Diagnostic Challenge. Voir source | 42437225 | 10.7759/cureus.110681 | Cureus | |
| Refractory Malignant Pericardial Effusion as the Initial Presentation of Early T-Cell Precursor Acute Lymphoblastic Leukemia/Lymphoma. Voir source | 42422651 | 10.7759/cureus.110468 | Cureus |
Sources officielles
liens de rechercheDernière mise à jour des données : 2026-10-19
Ces sources sont proposées pour vérification. Les informations de la fiche doivent être confirmées dans les registres officiels ou les publications originales.